pe cy7 anti mouse cd8α  (Multi Sciences (Lianke) Biotech Co Ltd)

Journal: Cell Reports Medicine

Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

doi: 10.1016/j.xcrm.2024.101567

Figure Lengend Snippet: rhIL-7-hyFc treatment increases PD-1 − bystander CD8 TILs (A‒E) scRNA-seq analysis of CD8 TILs. Mice bearing palpable MC38 tumors treated subcutaneously (s.c.) with rhIL-7-hyFc (10 mg kg −1 ). Tumors were collected 7 days after rhIL-7-hyFc treatment. Collected tumor tissues were pooled for analysis ( n = 5–7 per group). Unless specified otherwise, the data include TILs from both buffer- and rhIL-7-hyFc-treated mice. (A) UMAP plots of six distinct CD8 TIL clusters from MC38-bearing mice, numbered and colored according to the transcriptional clusters. (B) Dot plot showing the expression of various T cell-related genes in the six different clusters. (C) UMAP plot of top five expanded clones. (D) UMAP showing the distribution of expression of Pdcd1 transcript. (E) UMAP showing CD8 TIL clusters from buffer- or rhIL-7-hyFc-treated mice (left) and bar graph depicting the proportion of six clusters in each treatment condition (right). (F and G) rhIL-7-hyFc (10 mg kg −1 ) were treated s.c. in mice bearing various palpable tumors. Tumors were collected 7 days after rhIL-7-hyFc treatment ( n = 5–11 per group). (F) Frequency of PD-1 − CD8 T cells among total CD8 TILs. (G) Number of PD-1 + CD8 T cells (left) and PD-1 − CD8 T cells (right). Numbers on the bar indicate fold changes between buffer- and rhIL-7-hyFc-treated groups. Data are shown as mean ± SEM and representative of two independent experiments. (H) Schematic of clinical study design. Patients with metastatic colorectal and ovarian cancer were treated with rhIL-7-hyFc. Pre- and post-treatment tumor samples were collected during the screening period and at indicated time points. (I) Percentage of total CD8 T cells (left), PD-1 + CD8 T cells (middle), and PD-1 − CD8 T cells (right) among the total cells. Each dot represents a single region of interest (ROI) in each patient’s sample. The ROIs were manually designated by pathologists. (J) Representative immunofluorescence images of tumor biopsies from patient SB13. Purple, CD8; yellow, PD-1; gray, DAPI. Magnification, ×200, scale bars, 50 μm ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired (F, G, and I) two-tailed Student’s t test. See also Figures S1 ; Table S1 .

Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

Techniques: Expressing, Clone Assay, Immunofluorescence, Two Tailed Test

Journal: Cell Reports Medicine

Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

doi: 10.1016/j.xcrm.2024.101567

Figure Lengend Snippet: rhIL-7-hyFc treatment changes the transcriptome profiles of tumor-reactive and bystander CD8 TILs (A) UMAP of scTCR-seq data colored according to the clone size of expanded CD8 TILs from mice bearing MC38 tumors between groups (left) and a bar graph showing the proportion of CD8 TILs with each clone size between groups (right). (B) Number of DEGs in tumor-reactive and bystander CD8 TILs from tumor-bearing mice with rhIL-7-hyFc treatment compared with buffer treatment. (C) Top 5 enriched GO terms for up- or downregulated genes in tumor-reactive cells by rhIL-7-hyFc treatment. (D) Violin plots with an expression of genes related to T cell exhaustion, function, and TFs in tumor-reactive cells. (E) GSEA analysis with the gene set of exhausted vs. naive CD8 T cells (GEO: GSE9650 ), top TFs correlated with the dysfunctional program (Li et al. ), glycolysis (MSigDB: hallmark), and IFN-alpha response (MSigDB: hallmark) in tumor-reactive CD8 TILs. (F) Top 5 enriched GO terms for up- or downregulated genes in bystander cells by rhIL-7-hyFc treatment. (G) Violin plots with expression of genes related to ribosomal proteins, CM T cell, and T cell regulation in bystander cells. (H) GSEA analysis with the gene set of memory vs. exhausted CD8 T cells (GEO: GSE9650 ), positive regulation of TCR pathway (GO: 0050862 ), oxidative phosphorylation (MSigDB: hallmark), and IFN-alpha response (MSigDB: hallmark) in bystander CD8 TILs. Tumor-reactive cells are defined as cells with a clone size of 3 or greater, and bystander cells are defined as cells with a clone size of 1 or 2 and belonging to one of clusters 0, 2, 3, and 5. BIR., break-induced replication; DSBs., double-strand breaks; neg., negative; reg., regulation; sys., system; Pos., positive. See also Figures S2 and ; Table S2 .

Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

Techniques: Expressing, Phospho-proteomics

Journal: Cell Reports Medicine

Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

doi: 10.1016/j.xcrm.2024.101567

Figure Lengend Snippet: TCE stimulation elicits tumoricidal activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Schematic protein structure of PD-L1×CD3 TCE. This figure was created with BioRender.com . (B) The cytotoxicity of PD-L1 −/− splenocytes from naive PD-L1-deficient mice was evaluated. These splenocytes were co-cultured with CTV-labeled MC38 WT or MC38 ΔPD−L1 tumor cells in the presence of TCE at indicated concentrations for 48 h ( n = 3 per group). (C‒F) Functional assay of PD-L1×CD3 TCE on rhIL-7-hyFc-induced tumor-reactive and bystander CD8 TILs ( n = 3 per group). (C) Experimental scheme. (D) Expression of PD-1 and GzmB in PD-1 + or PD-1 − CD8 T cells co-cultured with MC38 in the presence of TCE at indicated concentration (left) and frequencies of PD-1 + GzmB + cells among CD8 T cells. Black and blue dots indicate PD-1 + and PD-1 − CD8 TILs before co-culture, respectively (right). (E) Frequencies of PD-1 + Prf + cells among CD8 T cells. (F) Cytotoxicity of PD-1 + and PD-1 − CD8 T cells in the presence of TCE. The expression of ghost dye in tumor cells was measured by flow cytometry. CTV + Ghost dye + cells are considered dead tumor cells. (G‒K) The functional changes and antitumor effects of rhIL-7-hyFc-expanded PD-1 − bystander CD8 T cells were investigated ( n = 5–7 per group). (G) Experimental scheme. MC38-bearing RAG1 −/− mice were injected i.t. with 4 × 10 6 CD8 + CD44 + CD62L + PD-1 − T cells sourced from the spleen and lymph nodes of C57BL/6 mice treated with rhIL-7-hyFc (10 mg kg −1 ). PD-L1×CD3 TCE (2 μg) or PBS was administered i.t. 5 times daily from the next day after T cell transfer. For flow cytometry analysis, tumors were collected 24 h after the second TCE treatment. (H) Average (left) and individual (right) tumor growth curves of MC38-bearing RAG1 −/− mice. The timing of TCE or PBS administration is indicated by blue or gray columns, respectively. (I) Representative plots showing the expression of GzmB in CD8 T cells (left) and frequency of GzmB + cells among CD8 T cells (right). (J) Representative plots showing the expression of Prf in CD8 T cells (left) and frequency of Prf + cells among CD8 T cells (right). (K) Representative plots showing the expression of Ki-67 in CD8 T cells (left) and frequency of Ki-67 + cells among CD8 T cells (right). Data are shown as mean ± SEM and representative of two or three independent experiments (B, D-F, and H) or a summary of two independent experiments (I–K). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by unpaired two-tailed Student’s t test (B, I, J, and K), by one-way ANOVA and Tukey’s multiple comparisons test (D–F), and by two-way ANOVA and Tukey’s multiple comparisons test (H). ns, not significant. See also Figures S3 and .

Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

Techniques: Activity Assay, Cell Culture, Labeling, Functional Assay, Expressing, Concentration Assay, Co-Culture Assay, Flow Cytometry, Injection, Two Tailed Test

Journal: Cell Reports Medicine

Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

doi: 10.1016/j.xcrm.2024.101567

Figure Lengend Snippet: TCE combination promotes the cytotoxic activity of rhIL-7-hyFc-induced bystander CD8 TILs (A) Experimental scheme. Mice bearing palpable MC38 tumors were injected s.c. with rhIL-7-hyFc (1.25 mg kg −1 ). Three days after rhIL-7-hyFc treatment, mice were treated i.v. with PD-L1×CD3 TCE (0.4 μg) 2 times daily. Twenty-four hours after the last treatment, mice were analyzed for TILs ( n = 4–6 per group). (B) Frequencies (left) and numbers (right) of CD8 T, CD4 T reg , CD4 non-T reg , and NK cells. (C) Frequencies of PD-1 − cells (left) and numbers of PD-1 + and PD-1 − cells among the total CD8 T cells (right). (D) Representative plots showing the expression of CD44 and CD62L in PD-1 − CD8 T cells. (E) Frequencies of CD44 + CD62L + (left) and CD44 + CD62L − (right) cells among PD-1 − CD8 T cells. (F, H, and I) Frequencies (left) and numbers (right) of GzmB + cells (F), Prf + cells (H), and Ki-67 + cells (I) among PD-1 − CD8 T cells. (G) Histogram of GzmB expression in PD-1 − CD8 T cells (left) and fold change of GzmB geometric mean fluorescence intensity (gMFI) compared with the buffer group in PD-1 − CD8 T cells. Data are shown as mean ± SEM and summary of two independent experiments (B, C, F, G, and I) or representative of two independent experiments (E and H). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 by one-way ANOVA and Tukey’s multiple comparisons test. ns, not significant. See also Figures S7 and .

Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

Techniques: Activity Assay, Injection, Expressing, Fluorescence

Journal: Cell Reports Medicine

Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

doi: 10.1016/j.xcrm.2024.101567

Figure Lengend Snippet: Transcriptome analysis of CD8 TIL subsets in combination therapy scRNA-seq results of CD8 TILs from mice bearing MC38 tumors treated with rhIL-7-hyFc alone or a combination of rhIL-7-hyFc and TCE. C57BL/6 mice bearing palpable MC38 tumors were injected s.c. with rhIL-7-hyFc (1.25 mg kg −1 ). Three days after rhIL-7-hyFc treatment, mice were treated i.v. with PD-L1×CD3 TCE (0.4 μg) three times daily. Tumors were collected 24 h after the last treatment. Collected tumor tissues were pooled for analysis ( n = 12 rhIL-7-hyFc and n = 24 combination). (A) UMAP plot showing each CD8 TIL cluster. (B) Supervised clustering of CD8 TILs according to gene-expression characteristics (left) and bar graph depicting the proportion of three CD8 TIL subclusters in each treatment condition (right). (C) Heatmap showing the DEGs between supervised groups. (D) Featured plots showing the expression of Pdcd1 (left) and Tcf7 (right) genes. (E) UMAP plot of top six most expanded clones. (F) Number of DEGs in each supervised CD8 TIL subcluster from mice with combination therapy compared with the rhIL-7-hyFc-treated group. (G) Dot plots of GO enrichment analysis of upregulated DEGs by combination therapy in each CD8 TIL subcluster. (H) Violin plots showing the expression of genes related to exhaustion, CM-associated, cytotoxicity, T cell activation, glycolysis, and cell motility. See also Figures S9 and ; Table S3 .

Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

Techniques: Injection, Gene Expression, Expressing, Clone Assay, Activation Assay

Journal: Cell Reports Medicine

Article Title: IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

doi: 10.1016/j.xcrm.2024.101567

Figure Lengend Snippet:

Article Snippet: Anti-mouse CD8α PE-Cy7 (clone: 53–6.7) , eBioscience , Cat# 25-0081-82; RRID: AB_469584.

Techniques: Purification, Recombinant, Formulation, Flow Cytometry, Amplification, Software, Staining

Journal: Journal for Immunotherapy of Cancer

Article Title: Type 17 immunity promotes the exhaustion of CD8 + T cells in cancer

doi: 10.1136/jitc-2021-002603

Figure Lengend Snippet: Tumor-infiltrating Tc17 cells exhibit tissue resident memory-like phenotypes in mice and humans. (A–E) Lung CD8 + tumor-infiltrating lymphocytes (TILs) in CD4-depleted B16F10 tumor-bearing C57BL/6 mice were analyzed. (A) Representative contour plots of cell surface expression of CD103 and KLRG1 on Tc17 and Tc1 cells. (B) PerCP-Cy5.5-labeled anti-mouse CD8α Ab was intravenously (i.v.) injected into CD4-depleted B16F10 tumor-bearing mice 5 min before sacrifice for analysis. Representative contour plots of CD8 α-PerCP-Cy5.5 + cells among total CD8 + T cells in spleen and lung tumor are shown. (C) Representative histogram of CD127 expression and frequencies of CD127 + cells of Tc17 and Tc1 cells (n=4). (D) Representative histogram of Ki-67 expression and frequencies of Ki-67 + cells of Tc17 and Tc1 cells (n=7). (E) Frequencies of granzyme B(GzmB) + cells of Tc17 and Tc1 cells (n=4). (F) Cytotoxicity of in vitro generated gp100-specific Tc1 cells or Tc17 cells (effector cells) against gp100-pulsed TC-1 tumor cells (target cells). Frequencies of Caspase-3(Casp3) + among CTV-labeled target cells were analyzed 4 hours after co-culture with effector cells. (G–J) CD8 + TILs isolated from tumor tissues of patients with hepatocellular carcinoma (HCC) were analyzed by flow cytometry. (G) Representative contour plots of IL-17 and IFN-γ production by Tc17 and Tc1 cells in TILs of patients with HCC and frequencies of Tc17 and Tc1 cells among CD8 + TILs (n=11). (H) Cell surface expression of CD103 and KLRG1 on each CD8 + T cell subset. (I) Representative histogram of cell surface expression of CD127 on each CD8 + TIL subset and frequencies of CD127 hi cells (n=6). (J) Representative histogram of GzmB expression in each CD8 + TIL subset and frequencies of GzmB + cells in each CD8 + TIL subset (n=6). Data are representatives of at least two independent experiments for (A–F) and (H–J) and combined results of two independent experiments for (G). Data are shown as mean±SD for (C-E, G, I, J) and mean±SEM for (F). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Article Snippet: For mouse sample flow cytometry analysis, lymphoid cells were obtained and stained with PerCP-Cy5.5 or PE-Cy7 anti-mouse CD8α (53-6.7; BioLegend), BUV395 or BUV737 anti-mouse CD8α (53-6.7; BD Biosciences), PerCP-Cy5.5 or APC anti-mouse CD4 (GK1.5; BioLegend), BV510 or PE-Cy7 anti-mouse CD4 (RM4-5; BioLegend), eFluor450 or PE-Cy7 anti-mouse CD90.2 (53-2.1; BioLegend), PerCP-Cy5.5 anti-mouse CD3ε (145-2 C11; BioLegend), BUV395 anti-mouse CD3ε (145-2 C11; BD Biosciences), Pacific Blue anti-mouse TCRβ (H57-597; BioLegend), APC anti-mouse γδTCR (GL-3; eBioscience), PE mouse CD1d tetramer (NIH Tetramer Core facility), APC anti-mouse/human KLRG-1 (2F1/KLRG1; BioLegend), APC-Cy7, FITC, or PE anti-mouse CD103 (2E7; BioLegend), Alexa Fluor 488, PerCP-Cy5.5 or Pacific Blue anti-mouse CD45.1 (A20; BioLegend), PerCP-Cy5.5, Pacific Blue, or BV510 anti-mouse CD45.2 (104; BioLegend), PE-Cy7 anti-mouse PD1 (RMP 1-30; BioLegend), PE or APC anti-mouse Tim3 (RMT3-23; eBioscience), APC or PE-Cy7 anti-mouse/human CD44 (IM7; BioLegend), Alexa Fluor 488 or PerCP-Cy5.5 anti-mouse CD62L (MEL-14; BioLegend), and PE-Cy7 or APC anti-mouse CD127 (A7R34; eBioscience).

Techniques: Expressing, Labeling, Injection, In Vitro, Generated, Co-Culture Assay, Isolation, Flow Cytometry

Journal: Cell reports

Article Title: Interleukin-27 Is Essential for Type 1 Diabetes Development and Sjögren Syndrome-like Inflammation

doi: 10.1016/j.celrep.2019.11.010

Figure Lengend Snippet:

Article Snippet: PE-Cy7 anti-mouse CD8α , Invitrogen , Clone 53–6.7, cat#25–0081–82; RRID:AB_469584.

Techniques: Purification, Recombinant, Staining, Cell Isolation, Enzyme-linked Immunosorbent Assay, Software